The objective of the Sub-Funds is to achieve increasing annual distributions together with long-term capital growth.
Name | % Net Assets |
---|---|
Merck & Co Inc (New) | 4.6% |
BP PLC | 4.0% |
Royal Dutch Shell PLC | 3.2% |
GlaxoSmithKline PLC | 3.1% |
British American Tobacco PLC | 2.8% |
Deutsche Telekom AG | 2.3% |
Centrica PLC | 2.2% |
Singapore Tech Engineering Ltd | 2.2% |
Novartis AG | 2.1% |
Unilever NV | 2.1% |
Key | % Net Assets |
---|---|
Merck & Co Inc (New) | 4.6% |
BP PLC | 4.0% |
Royal Dutch Shell PLC | 3.2% |
GlaxoSmithKline PLC | 3.1% |
Other | 85.1% |
Date | 21-Nov-2024 |
---|---|
NAV | 270.52p |
Currency | GBP |
Change | -1.08p |
% | -0.40% |
YTD change | 14.33p |
YTD % | 5.59% |
Fund Inception | 30/11/2005 |
---|---|
Fund Manager | n/a |
TER | 1.62 (30-Dec-2011) |
Minimum Investment | |
---|---|
Initial | £1000 |
Additional | n/a |
Savings | £50 |
Charges | |
---|---|
Initial | 4.00% |
Annual Mang't | 1.50% |
Exit | n/a |
Name | % |
---|---|
Standard deviation | 0.02 |
Sharpe ratio | 0.10 |
You are here: research